Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) FCF Margin: 2013-2017

Historic FCF Margin for Soleno Therapeutics (SLNO) over the last 3 years, with Jun 2017 value amounting to -299,100.00%.

  • Soleno Therapeutics' FCF Margin fell 9710000.00% to -299,100.00% in Q2 2017 from the same period last year, while for Jun 2017 it was -1,211.64%, marking a year-over-year increase of 26980.00%. This contributed to the annual value of 30,007.79% for FY2024, which is N/A change from last year.
  • Soleno Therapeutics' FCF Margin amounted to -299,100.00% in Q2 2017, which was down 36,142.11% from -825.28% recorded in Q1 2017.
  • Soleno Therapeutics' FCF Margin's 5-year high stood at 232.86% during Q4 2013, with a 5-year trough of -299,100.00% in Q2 2017.
  • Over the past 3 years, Soleno Therapeutics' median FCF Margin value was -1,197.74% (recorded in 2015), while the average stood at -51,801.95%.
  • Within the past 5 years, the most significant YoY rise in Soleno Therapeutics' FCF Margin was 733,175bps (2016), while the steepest drop was 19,921,649bps (2016).
  • Over the past 5 years, Soleno Therapeutics' FCF Margin (Quarterly) stood at 232.86% in 2013, then plummeted by 16,579bps to 67.07% in 2014, then crashed by 136,499bps to -1,297.92% in 2015, then skyrocketed by 35,292bps to -944.99% in 2016, then slumped by 9,710,000bps to -299,100.00% in 2017.
  • Its last three reported values are -299,100.00% in Q2 2017, -825.28% for Q1 2017, and -944.99% during Q4 2016.